Senior Product Manager, (HCP) Healthcare Practitioner Marketing, Oncology
Foster City, CA (Hybrid)
$154K/yr – $219K/yrSenior LevelFull time
Posted 4 days ago
Job Summary
Original Job Description
Gilead Sciences
At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and we’re all united in our commitment to help millions of people live healthier lives.Social Media Guidelines: https://www.gilead.com/social-media-guidelines
Marketing team
773
Employees
15K
Headquarters
San Mateo, California, USA
Founded
1987
Employee Sentiment
Overall Rating
3.8 / 5
Recommend to a Friend
74%
CEO Approval
80%
Source: Glassdoor
Traffic Signals
Monthly Visitors
651.4K
Monthly Google Ads Budget
$0.0
Traffic Source Mix
Search
32.1%
Direct
49.6%
Referral
16.3%
Social
0.9%
Paid
0.9%
Headcount Trend
Current headcount: ~14.6K
Funding
Total Funding
$4.4B
Last Raise
1 years ago
Last Raise Amount
$3.5M
- 2024-11-13Post IPO Debt • $3.5M
- 2024-02-29Post IPO Equity • $210.0M
- 2023-09-07Post IPO Debt • $2.0B
Recent News
Yahoo Finance
Why The Narrative Around Gilead Sciences Is Shifting After HIV And Oncology Updates
Dec 7, 2025
Seeking Alpha
Gilead Sciences: About To Break Out (NASDAQ:GILD)
Nov 25, 2025
BioPharma Dive
Gilead scoops up a preclinical cancer program
Nov 25, 2025
Fierce Biotech
Gilead abruptly parts ways with general counsel—Chutes & Ladders
Nov 21, 2025
Yahoo Finance
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
Nov 20, 2025
Yahoo Finance
Gilead Sciences (GILD): Taking Stock of Valuation as Shares Approach Analyst Targets
Nov 19, 2025
European AIDS Treatment Group
Gilead’s investigational single-tablet regimen of bictegravir and lenacapavir for HIV-1 treatment meets primary endpoint in Phase 3 ARTISTRY-1 trial
Nov 13, 2025
Yahoo Finance
Assessing Gilead After 34% Rally and Recent Pharmaceutical Partnerships
Nov 12, 2025
Yahoo Finance
How Recent Developments Are Shaping the Gilead Sciences Investment Story
Nov 8, 2025
Yahoo Finance
Gilead Sciences’s Q3 Earnings Call: Our Top 5 Analyst Questions
Nov 5, 2025
Business Wire
Gilead Sciences to Present at Upcoming Investor Conferences
Nov 4, 2025
Yahoo Finance
Gilead Sciences (GILD) Profit Margin Surge Reinforces Bullish Narratives on Operational Turnaround
Oct 31, 2025
Fierce Pharma
Gilead's long-acting PrEP Yeztugo takes off while cell therapy declines continue to haunt sales
Oct 31, 2025
Business Wire
Gilead Sciences Announces Third Quarter 2025 Financial Results
Oct 30, 2025
Fierce Biotech
Gilead ends phase 1 trial after settling on twice-yearly treatment partner for lenacapavir
Oct 30, 2025
Yahoo Finance
Gilead Sciences (NASDAQ:GILD) Exceeds Q3 Expectations
Oct 30, 2025
Reuters
Gilead posts higher profit on demand for HIV drugs, but overall sales dip
Oct 30, 2025
Yahoo Finance
Liver Drug Approval and Pipeline Data Could Be a Game Changer for Gilead Sciences (GILD)
Oct 29, 2025
Yahoo Finance
Gilead Sciences (GILD) Reports Q3: Everything You Need To Know Ahead Of Earnings
Oct 28, 2025
TIKR.com
Gilead Sciences Stock Forecast: Where Analysts See the Stock Going by 2027
Oct 25, 2025
Yahoo Finance
Gilead Sciences Rallies 32% in 2025 Are Shares Trading Below Their True Value
Oct 23, 2025
Yahoo Finance
Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know
Oct 22, 2025
Investing.com
Gilead Sciences stock rating reiterated by RBC amid HIV drug setback
Oct 22, 2025
Investor's Business Daily
Gilead Sciences Shows Market Leadership With Jump To 83 RS Rating
Oct 20, 2025
Seeking Alpha
Gilead Sciences Breaks Out To Record Highs, The Rally Has Room To Run
Oct 18, 2025
Yahoo Finance
A Look at Gilead Sciences’s Valuation Following Breakthrough HIV and Cancer Clinical Trial Results
Oct 17, 2025
FirstWord Pharma
Gilead, Roche latest to tap Chinese firms for drug development
Oct 17, 2025
European AIDS Treatment Group
Gilead presents new HIV research data at EACS 2025 – driving scientific innovation in treatment and prevention
Oct 15, 2025
Clinical Trials Arena
Gilead to present data on potential first weekly oral treatment for HIV
Oct 15, 2025
Yahoo Finance
How Investors Are Reacting To Gilead Sciences (GILD) Extending Biktarvy Exclusivity and Advancing HIV, Oncology Pipeline
Oct 11, 2025
Morningstar
Gilead: Incorporating Longer Biktarvy Runway
Oct 10, 2025
Gilead Sciences
A Look Inside Gilead's Inflammation Pipeline
Oct 9, 2025
Business Wire
Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025
Oct 9, 2025
Yahoo Finance
Gilead Sciences Rallies After Trump Partnership News Is the Growth Story Just Beginning
Oct 8, 2025
Fierce Pharma
Gilead inks trio of Biktarvy patent settlements, waylaying US copycats until 2036
Oct 7, 2025
Partnership for Safe Medicines
Case overview, Gilead Sciences v Meritain Health, et al
Oct 4, 2025
Yahoo Finance
Gilead Sciences (GILD) Laps the Stock Market: Here's Why
Oct 3, 2025
Yahoo Finance
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Oct 2, 2025
Gilead Sciences
Gilead Oncology Grantee Provides Practical Support for Patients Undergoing Breast Cancer Treatment
Oct 1, 2025
Yahoo Finance
What Do Analysts Think About Gilead Sciences (GILD)?
Sep 30, 2025
PR Newswire
Health Hope Pharma Enters into Exclusive Licensing Agreement with Gilead Sciences
Sep 29, 2025
Fierce Biotech
Gilead pumps up virology pipeline with drug transporter deal
Sep 29, 2025
Yahoo Finance
Morgan Stanley Maintains Buy on Gilead Sciences (GILD)
Sep 28, 2025
Yahoo Finance
Gilead Sciences (GILD) Stock Sees Positive Outlook Amid HIV, Liver, and Cancer Drug Momentum
Sep 26, 2025
Pharmafile
Gilead Foundation awards $6.5m in grants to support STEM education
Sep 26, 2025
Yahoo Finance
JPMorgan Lifts Gilead Sciences, Inc. (GILD)’s Price Target To $145, Maintains Overweight Rating
Sep 26, 2025
BioSpace
Gilead Foundation Grants $6.5 Million in Commitment to STEM Education
Sep 26, 2025
Yahoo Finance
Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors
Sep 25, 2025
Seattle TechFlash
Gilead drug deal opens door for $40-a-year generic version of groundbreaking HIV prevention overseas
Sep 25, 2025
Yahoo Finance
Why Gilead Sciences (GILD) Deserves Attention in the Cheap Quarterly Dividend Stocks Category
Sep 25, 2025
Fast Company
Bill Clinton calls out aid cuts, political unrest, and more at the Clinton Global Initiative
Sep 25, 2025
Yahoo Finance
Gilead Sciences Surges 26.5% YTD: Buy, Sell or Hold the Stock?
Sep 24, 2025
WPEC
Florida AG announces $3M settlement with Gilead Sciences over improper HIV drug promotion
Sep 24, 2025
NYT > Business
Philanthropies Strike a Promising Deal to Turn Back H.I.V.
Sep 24, 2025
IndiaTimes
Lupin gets tentative nod from USFDA for generic HIV treatment drug
Sep 24, 2025
STAT
STAT+: Global health groups push to make cheap generic versions of an HIV prevention drug sold by Gilead
Sep 24, 2025
Business Standard India
Lupin gets tentative nod from USFDA for generic HIV treatment drug
Sep 24, 2025
AllAfrica.com
Zimbabwe to Roll Out Breakthrough HIV Prevention Drug
Sep 24, 2025
Pharma Letter
Activists demand $40-a-year generic PrEP
Sep 24, 2025
semafor.com
Child mortality at risk of rising in 2025 for first time this century: Gates Foundation
Sep 24, 2025
Seeking Alpha
Gilead Sciences: Yeztugo And Trodelvy Make This A Buy Once More (NASDAQ:GILD)
Sep 23, 2025
Neo4j
Gilead Sciences Combats $431 billion Pharmaceutical Fraud Threat with Neo4j Graph Analytics
Sep 23, 2025
Yahoo Finance
Did Gilead's (GILD) $32 Billion AI Bet Just Transform Its Innovation and Global Health Narrative?
Sep 22, 2025
Yahoo Finance
Gilead Sciences, Inc. (GILD) Expands U.S. Manufacturing Capacity With $32B Investment Through 2030
Sep 21, 2025
STAT
STAT+: CDC recommends new Gilead HIV prevention drug, prompting advocates to push CVS for coverage
Sep 19, 2025
Yahoo Finance
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
Sep 18, 2025
BioSpace
Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis
Sep 18, 2025
Morningstar.com
Marengo Therapeutics Advances STARt-002 Clinical Trial into Phase 2 Cohort Expansion Evaluating Invikafusp Alfa with TROP2-directed ADC TRODELVY® in Metastatic Breast Cancer
Sep 18, 2025
Investing.com
Moody’s affirms Gilead’s A3 rating, revises outlook to positive
Sep 18, 2025
BioSpace
Marengo Therapeutics Advances STARt-002 Clinical Trial into Phase 2 Cohort Expansion Evaluating Invikafusp Alfa with TROP2-directed ADC TRODELVY® in Metastatic Breast Cancer
Sep 18, 2025
Fangzhou Inc.
Fangzhou Wins Gilead ‘Award of Excellence’ for AI-Driven Chronic Disease Management
Sep 18, 2025
PR Newswire
Marengo Therapeutics Advances STARt-002 Clinical Trial into Phase 2 Cohort Expansion Evaluating Invikafusp Alfa with TROP2-directed ADC TRODELVY® in Metastatic Breast Cancer
Sep 18, 2025
thefly.com
Nurix Therapeutics presents data from GS-6791
Sep 17, 2025
Nurix Therapeutics, Inc.
Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis
Sep 17, 2025
AllAfrica.com
Namibia: Trump Cuts Leave 4,000 Namibian Health Workers Facing the Sack
Sep 17, 2025
Yahoo Finance
Redburn Atlantic Maintains a Buy on Gilead Sciences (GILD), Sets a $143 PT
Sep 16, 2025
CA.gov
Global biotech leaders Amgen and Gilead announcing expansions in California, the #1 state for life sciences
Sep 15, 2025
Investing.com
Gilead Sciences stock price target raised to $143 from $136 at Rothschild Redburn
Sep 12, 2025
Reuters
Gilead beats whistleblower lawsuit over hepatitis C drugs
Sep 12, 2025
Contract Pharma
Gilead Sciences Commits to Veeva Vault CRM
Sep 10, 2025
PR Newswire
Gilead Sciences Commits to Veeva Vault CRM
Sep 10, 2025
AIDS Healthcare Foundation
Gilead Price Hikes Screw ADAP Programs, HIV Patients--AHF Protest
Sep 9, 2025
MarketScreener
Xilio starts phase 2 trial for XTX301, hits $17.5M milestone in Gilead license deal
Sep 9, 2025
MarketScreener
Transcript : Gilead Sciences, Inc. Presents at Morgan Stanley 23rd Annual Global Healthcare Conference, Sep-09-2025 10
Sep 9, 2025
IAM Patent
Gilead Sciences says remdesivir-copy patent in UPC action worth €20 million
Sep 8, 2025
Business Wire
Bicycle Therapeutics Strengthens Board of Directors with New Appointments
Sep 8, 2025
PR Newswire
IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer
Sep 8, 2025
Pharma Letter
The Pharma Letter M&A roundup - August 2025
Sep 8, 2025
Business Wire
Australia Acute Respiratory Distress Syndrome Market Analysis 2025-2033 | Disease Burden, Rising ICU Admissions, and Advancements in Medical Technology Drive ARDS Growth - ResearchAndMarkets.com
Sep 8, 2025
PR Newswire UK
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market
Sep 8, 2025
PR Newswire
WACO Theater Center Announces Still Here Live Experience In Los Angeles Supported By Gilead Sciences, Inc.
Sep 8, 2025
Yahoo Finance
Leerink Partners Maintains Buy on Gilead Sciences (GILD)
Sep 7, 2025
Pharmaceutical Technology
Gilead Sciences advances HIV prevention with new US partnership
Sep 5, 2025
Genetic Engineering and Biotechnology News
Gilead Sciences Breaks Ground on New Biomanufacturing Hub
Sep 5, 2025
RCR Wireless News
Gilead Sciences sets $32bn plan for AI-geared pharma factories in the US
Sep 5, 2025
Business Wire
Gilead Sciences Launches Choose U Campaign Spotlighting the Inspiring Experiences of People Living with HIV
Sep 4, 2025
Fierce Pharma
Gilead urges people living with HIV to 'Choose U' in campaign touting long-term treatment success
Sep 4, 2025
The Pharma Letter
Gilead Sciences breaks ground on new manufacturing hub
Sep 4, 2025
Reuters
US plans to bring Gilead HIV drug to market in high-burden HIV countries
Sep 4, 2025
U.S. Department of State (.gov)
Department of State, Gilead Sciences, and The Global Fund Announcement of Lifesaving and Innovative PEPFAR Initiative
Sep 4, 2025